Marksans Pharma (MARKSANS)₹308.75+1.65%Pharmaceuticals
At the end of the Jun 2026 quarter, Marksans Pharma's shareholders were: promoters 43.88%, FIIs 17.51%, DIIs 6.24%, public 32.37%. Promoter holding is unchanged on the quarter. FII holding is down 2.42 percentage points from 19.93% a year earlier. It had 2,46,604 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 43.86% | 43.86% | 43.86% | 43.88% | 43.88% | 43.88% | 43.88% | 43.88% | 43.88% | 43.88% | 43.88% | 43.88% |
| FIIs | 15.11% | 15.59% | 15.61% | 18.63% | 21.35% | 21.99% | 22.23% | 19.93% | 16.96% | 8.17% | 16.80% | 17.51% |
| DIIs | 4.06% | 4.80% | 5.22% | 3.78% | 4.14% | 4.34% | 4.59% | 5.55% | 5.33% | 5.96% | 6.62% | 6.24% |
| Public | 36.97% | 35.75% | 35.31% | 33.71% | 30.63% | 29.79% | 29.30% | 30.64% | 33.83% | 41.99% | 32.70% | 32.37% |
| Number of shareholders | 2,07,911 | 2,37,347 | 2,54,667 | 2,35,471 | 2,48,814 | 2,59,781 | 2,57,241 | 2,56,189 | 2,65,755 | 2,55,121 | 2,46,248 | 2,46,604 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Mark Saldanha | Promoter | 43.81% | 0.00 |
| Orbimed Asia Iv Mauritius Fvci Limited | FII | 8.59% | 0.00 |
| Uti-Healthcare Fund | DII | 2.12% | −0.38 |
| Kotak Mahindra Trustee Co Ltd A/C Kotak Special Opportunities Fund | DII | 1.13% | +0.01 |
| Sandra Saldanha | Promoter | 0.07% | 0.00 |
Promoters held 43.88% of Marksans Pharma at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 17.51% (up 0.71 percentage points from 16.80% a quarter earlier) and domestic institutions (DIIs) held 6.24% (down 0.38 percentage points from 6.62% a quarter earlier).
Marksans Pharma had 2,46,604 shareholders at the end of the Jun 2026 quarter, against 2,56,189 a year earlier.
Orbimed Asia Iv Mauritius Fvci Limited (FII) held 8.59% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.